摘要
目的 观察沙利度胺治疗难治性、复发性多发性骨髓瘤(MM)的疗效和毒副反应,并从IL-6、sIL-R水平探索沙利度胺治疗多发性骨髓瘤有效的可能机制。方法 用随机分组的方法观察和比较沙利度胺组和VIDM对照组的部分缓解(PR)率、总有效率、达到PR所需的时间;用双抗夹心法ELISA检测沙利度胺组治疗前后MM患者血清IL-6、sIL-6R的变化情况。结果 沙利度胺组的PR率和总有效率为50.0％、69.2％,分别高于对照组的40.9％、59.1％(P<0.05);达到PR所需的中位时间沙利度胺组为69 d,明显长于VIDM组的46 d(P<0.05)。沙利度胺组治疗后MM患者血清IL-6、sIL-6R的水平分别为180.3±101.3 ng/L、178.2±56.9 μg/L,均明显低于治疗前的564.8±319.4 μg/L、253.5±130.5 ng/L(P<0.05)。结论 沙利度胺是一种有效且副作用小的治疗难治性、复发性多发性骨髓瘤的药物,无严重不良反应。它可能还通过减少MM患者IL-6、sIL-R水平发挥抗瘤作用。
Objective To observe results,toxicity and adverse effects for thalidomide in treating refratory and replased multiple myeloma (MM), and to explore efficacious mechanism for thalidomide to treat refratory and replased MM from IL-SIL-6R. Methods Part remission (PR) rate, total response rate, the days reaching PR were observed.The levels of serum IL^sIL-6R before and after treated by thalidomide were measured by with filling double antibody EL1SA. Results PR rate and total response rate of thalidomide group were 50.0% ,69.2%, which were higher than 40.9% ,59.9% of control,respectively (P < 0.05) .The average days reaching PR were 69 in thalidomide group, which was longer than 46 in VIDM group( P < 0.05). The level of serum IL-6, sIL- R after treated by thalidomide were 180. 3 ± 101. 3 ng/L, 178. 2 ± 56. 9 ug/L. They were all lower than 564. 8 ± 319.4 ng/L,253.5± 130.5 ug/L before treated by thalidomide(P<0.05).Conclusion Thalidomide is effective and safe drug to refractory and replased MM. It has little serious toxicity and adverse effect. It plays an antitumor regimen maybe through decreasing level of serum IL-6,sIL-6R.
出处
《中国肿瘤临床与康复》
2003年第2期120-123,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
